Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HSCI / HK Connect June 2026: Pre-Implementation Update

HSCI / HK Connect June 2026 Implementation: Post-Implementation Review

HSCI / HK Connect May 2026 Review Forecast

HSCI / HK Connect (March 2026) Post-Event Review: What Worked, What Didn't

HSCI / HK Connect (March 2026): Implementation Today & Positioning

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>Hang Seng announced six immediate Connect ADDs and zero DELETEs, effective 8 Jun 2026. Three delayed ADDs remain outside this study pending stock splits.</li>
<li>Our 4 May forecast called five of six ADDs correctly.</li>
<li>Pre-Announcement cohort return matched history, but stock dispersion was far wider than prior cycles. Opening-gap size should drive bridge-window entry.</li>
</ul>


Hang Seng announced six immediate Connect ADDs and zero DELETEs, effective 8 Jun 2026. Three delayed ADDs remain outside this study pending stock splits.
Our 4 May forecast called five of six ADDs correctly.
Pre-Announcement cohort return matched history, but stock dispersion was far wider than prior cycles. Opening-gap size should drive bridge-window entry.


Beijing Haizhi Technology Group (2706 HK)

HSCI / HK Connect June 2026 Implementation: Post-Announcement Positioning

Z.AI

HSCI / HK Connect June 2026 Implementation: Post-Announcement Positioning